Relapses following chemotherapy are a major hindrance to patients' survival in acute myeloid leukemia (AML). To investigate the role of the hematopoietic niche in the chemoresistance of leukemic cells, we examined two pathways: one mediated by adhesion molecules/integrins, and the other by soluble factors of the morphogen Wnt pathway. In our study, both the adhesion of leukemic blasts to fibronectin and the addition of Wnt antagonists induced, independently, resistance of AML cells to daunorubicin in a cell survival assay. Using pharmacological inhibitors and siRNA, we showed that both resistance pathways required the activity of the glycogen synthase kinase 3b (GSK3b). Moreover, the AML cell protection downstream of GSK3b was mediated by NF-jB. A link between the adhesion and the Wnt pathway was found, as adhesion of U937 on human osteoblasts, a component of the hematopoietic niche, triggered the secretion of the Wnt antagonist sFRP-1 and supported resistance to daunorubicin. The osteoblast-conditioned medium could also confer chemoresistance to U937 cells cultured in suspension, and this cell protective effect was abrogated after depletion of sFRP-1. In the context of this potential double in vivo resistance, modulators of the common signal GSK3b and of its target NF-jB could represent important novel therapeutic tools.
Introduction
A major problem in the treatment of acute myeloid leukemia (AML) remains the recurrence of the pathology following chemotherapy. This common and severe complication is due to resistant leukemic cells which are localized in bone marrow. In the hematopoietic niche, specific components of the microenvironment could be responsible for leukemic cell resistance to drug. It has been demonstrated in several hematological malignancies that cell/cell or cell/matrix adhesion processes are involved in chemoresistance (Hazlehurst et al., 2003) . Moreover, the integrin a 4 b 1 which mediates adhesion of hematopoietic cells onto the extracellular matrix (fibronectin) or stromal cells has recently been involved in cell adhesion-mediated drug resistance (CAM-DR) of AML in vitro and in vivo (Matsunaga et al., 2003) .
In the hematopoietic niche, stem cell regulators (Wnt, Notch, Sonic Hedgehog) could also influence drug sensitivity of AML (Dean et al., 2005) . Recent studies from Weissman's group have demonstrated that the morphogen Wnt-dependent signaling is involved in self-renewal and survival of hematopoietic progenitors (Reya et al., 2003) , as well as in leukemic potential of leukemic progenitors (Jamieson et al., 2004) . Moreover, constitutive activation of the Wnt signaling pathway was found in AML (Simon et al., 2005) and several translocations in AML promote its activation (Muller-Tidow et al., 2004) . The Wnt ligands and antagonists are secreted by osteoblasts (Westendorf et al., 2004) providing support to hematopoiesis (Calvi et al., 2003) , or by hematopoietic cells themselves (Reya et al., 2003) . However, their potential role in the response of AML to treatment remains unknown. Different levels of cross-talk exist between adhesion molecules and morphogens. For example, it was shown that the interaction of cells with the extracellular matrix via integrins determines Wnt-1 expression (Czyz and Wobus, 2001) , and that the Wnt-dependent signaling pathway controls fibronectin expression (Gradl et al., 1999) . Recent data indicate that antagonists of Wnt pathway (secreted Frizzled-related protein (sFRP); Dkk, Dickkopf) could modulate adhesion/migration or chemosensitivity of several cancer cells (Roth et al., 2000; Shou et al., 2002; Hoang et al., 2004; Lee et al., 2004) . Depending on the model, the inhibition of Wnt signaling pathway might induce positive or negative effects on chemosensitivity and adhesive functions. Adhesion and Wnt-dependent signals use several common signaling pathways. The oncogenic protein b-catenin is differentially localized and regulated upon engagement of receptors of cell/cell junctions (cadherins), integrins or Wnt receptors (Frizzled) (Yoganathan et al., 2002; Nelson and Nusse, 2004) . b-Catenin has been involved in the regulation of leukemic cell adhesion, proliferation, and survival (Chung et al., 2002; Hwang et al., 2002) . Among other targets shared by integrins and Wnt pathway is the transcriptional regulator, NF-kB, which plays a key role in cell survival (Scatena et al., 1998; Bournat et al., 2000) . A constitutive activation of NFkB in AML has been described (Guzman et al., 2001) and its inhibition contributes specifically to apoptosis induction in leukemic stem cells (Guzman et al., 2002) . Upstream of b-catenin and NF-kB, the glycogen synthase kinase 3b (GSK3b) has been shown to control b-catenin (Yoganathan et al., 2002) and NF-kB (Hoeflich et al., 2000) activities, and can be regulated by integrins and the Wnt pathway.
The purpose of this study was to evaluate the influence of integrin and Wnt-dependent signaling pathways on the chemosensitivity of AML. The mechanism of the integrin/Frizzled cross-talk in the context of drug response is presently unknown. Using AML fresh blasts and cell lines, we demonstrate here that both adhesion and Wnt pathways modulate the chemosentivity of AML to anthracyclins through a GSK3b/ NF-kB-dependent pathway. Moreover, adhesion of leukemic cells on osteoblasts enhances their drug resistance and triggers Wnt antagonist secretion.
Results
CAM-DR of AML cells occurs in the absence of serum and is mediated through a 4 b 1 and a 5 b 1 integrins engagement We have first delineated experimental conditions allowing CAM-DR studies with the U937 leukemic cell line and fresh blasts. Serum withdrawal (1 h) was required to obtain cell adhesion onto fibronectin (80%) and death in response to daunorubicin (DNR) (40-60%). Cell adhesion onto fibronectin (1 h) was followed by 1 h of DNR treatment in the absence of serum and subsequent incubation of cells with serum for 24 h. Under these conditions, CAM-DR could be measured in U937 and blasts from patients ( Figure 1a ). Among the 35 AML patients tested, 50% displayed CAM-DR (cell survival after DNR treatment in adhesion compared to suspension: þ 25%, n ¼ 17, Figure 1a) . No significant correlation with biological or clinical features (age, WBC, FAB subtype, cytogenetic, FLT3-ITD, CD34 or CD117 expression, complete remission, relapse) was observed.
U937 displayed CAM-DR similarly to fresh blasts (cell survival after DNR treatment in adhesion compared to suspension: þ 22%, n ¼ 19). Therefore, the following experiments were performed with blasts from patients or U937 cells. Cell cycle analysis of PI-labeled U937 by FACS revealed no difference in cell cycle repartition in controls in adhesion or in suspension. After DNR treatment, a smaller sub-G1 fraction in DNR-treated U937 in adhesion (31%) versus suspension (56%) was measured, indicating that cell death due to apoptosis was decreased in adherent cells (not shown). Moreover, adhesion of U937 before DNR treatment prevented the cleavage of caspase 3 and its substrate PARP (Figure 1b ). Since reduced cell death in adherent DNRtreated U937 was confirmed by different techniques, without evidence of changes in the cell proliferation status, we used the MTT assay to measure cell survival variations in further experiments. Figure 1 Adhesion protects AML from genotoxic stress. (a) Fresh blasts from AML patients and U937 cells were serum starved for 1 h and then plated on fibronectin (Fn) or plastic coated with antibodies directed to a 4 or a 5 integrin subunits. DNR (0.5 mM) was added for 1 h and after washing, cells were incubated with serum for 24 h. Surviving cells were estimated by a MTT test. Data from patients (n ¼ 17) or from U937 (n ¼ 19) are expressed as percent of survival compared to the controls without DNR (suspension or adhesion). Two independent experiments have been performed with each anti-integrin antibody and an isotype control with mouse IgG 3 is shown. In the insert, a dose-response curve to a 4 or a 5 antibodies in a competitive cell adhesion assay demonstrate the involvement of both a 4 b 1 and a 5 b 1 integrins in the adhesion of U937 on fibronectin. (b) U937 were allowed to adhere on fibronectin (A) or maintained in suspension (S) and treated by DNR. Western-blotting of caspase 3 and its substrate (PARP) have been performed onto lysates obtained in the different conditions.
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In our experimental conditions, U937 adhesion onto fibronectin was mediated by both a 4 b 1 and a 5 b 1 integrins as indicated by the use of specific blocking antibodies against a 4 or a 5 subunits (Figure 1a, insert) . As shown in Figure 1a , coated antibodies directed to a 4 or a 5 supported CAM-DR to the same extent as fibronectin. Coating with irrelevant antibodies (mouse IgG 3 ) was not able to support CAM-DR (Figure 1a) .
Downstream of integrin engagement, signaling pathways regulated by FAK and phosphoinositide 3-kinase (PI 3-kinase) play a major role in cell survival. Our previous data (Recher et al., 2004) have shown that FAK-negative blasts adherent on fibronectin displayed CAM-DR. Moreover, U937 did not express FAK in our culture conditions even after 12 h of cell adhesion onto fibronectin (Recher et al., 2004 and not shown) . The use of PI 3-kinase inhibitors (wortmannin, 100 nM; LY294002, 10 mM) increased chemosensitivity of U937, both in suspension and in adhesion, but CAM-DR was maintained ( þ 21% in LY294002 assays versus þ 27% in controls, n ¼ 8, not shown).
Altogether, these results show that CAM-DR in AML could occur independently of serum factors, implies different types of integrins and differs from the classical FAK and PI 3-kinase-dependent pathways.
Modulation of the Wnt pathway regulates chemosensitivity of AML Since Wnt antagonists (sFRP) have been shown to induce resistance to apoptotic signals in several cancer cells, we examined this question for AML. Addition of sFRP-1 to blasts or U937 cells induced resistance to DNR ( þ 16 and þ 20% increase of survival, respectively) as shown in Figure 2a . Conversely, incubation with the Wnt agonist, Wnt3a, increased chemosensitivity of U937 and blasts ( Figure 2a) . Notably, addition of sFRP-1 or Wnt3a did not change adhesion properties (not shown) nor drugsensitivity of adherent cells (Figure 2a) .
b-Catenin being a common target of both Wnt and cell adhesion pathways, its variations were measured using Western blotting in our conditions. The b-catenin expression level in U937 was strongly decreased or increased upon sFRP-1 or Wnt3a treatment, respectively (Figure 2b ), but was not changed upon adhesion onto fibronectin (not shown). Moreover, siRNA directed to b-catenin did not significantly modify U937 survival (not shown) despite a strong decrease of the protein level (>80%).
These data show that inhibition of the Wnt pathway in leukemic cells triggers chemoresistance as efficiently as cell adhesion. The mechanisms involved in cell resistance are not correlated with the level of b-catenin but might involve other targets shared by both pathways.
GSK3b regulates AML survival and is a common effector of both integrins and Wnt pathways GSK3b, a proximal target of both integrins and Wnt receptors, was inhibited by pharmacological inhibitors or by siRNA. Since proteasomal degradation of b-catenin is decreased by GSK3b inhibition, we checked the efficiency of GSK3b inhibitors using Western blottting of b-catenin ( Figure 3a , right panel). Data obtained in U937 and blasts with different pharmacological inhibitors, or siRNA, demonstrate that GSK3b activity is required for chemoresistance induced by cell adhesion (Figure 3a , left and right panels). The survival of DNR-treated AML cells in suspension was not significantly modified by GSK3b inhibition (Figure 3a , right panel), suggesting that the GSK3b-dependent pathway could have controlled specifically CAM-DR. It should be noted that GSK3b inhibitors did not impair cell adhesion onto fibronectin (not shown).
Western blot analysis using an antibody specific for inactive GSK3b (GSK3 phosphorylated at serine 9) showed that GSK3b was not phosphorylated in adherent U937 by contrast with cells in suspension, suggesting that GSK3b activity is triggered by cell adhesion ( Figure 3b ).
As shown in Figure 4 , GSK3b inhibition by LiCl (10 mM) abrogated drug resistance induced by different antagonists of the canonical Wnt/b-catenin pathway (sFRP-1, Dkk-1, Wnt5a).
These data demonstrate that GSK3b plays a key role in the chemoresistance mediated by cell adhesion or Wnt inhibition. Adhesion and Wnt pathways in chemoresistance of AML F De Toni et al NF-kB is required for drug resistance and is regulated by GSK3b in AML Since NF-kB is a potential target of GSK3b-dependent cell survival pathway and has been shown to be involved in cell survival of AML, we checked its involvement in adhesion-or sFRP-1-mediated drug resistance. Using siRNA directed to the NF-kB family member p65 (Rel A/ p65), we show that NF-kB is required for drug resistance mediated by both cell adhesion and the Wnt antagonist sFRP-1 (Figure 5a ). Cell survival of DNR-treated U937 in suspension ( Figure 5a ) and cell adhesion on fibronectin (not shown) were not modified by p65 decrease.
Measurement of NF-kB activity in U937 cells by gel electrophoretic mobility shift assays (EMSA) showed a significant basal activity ( Figure 5b ) reflecting constitutive activity in AML. However, an increased activity was measured upon adhesion whereas pretreatment with LiCl restored basal activity (Figure 5b ), indicating that GSK3b could regulate NF-kB activity. Notably, variations of NF-kB activity in adherent U937, or after LiCl treatment, were not correlated with significant decrease or increase in IkB level, respectively (Figure 5c ), suggesting that: (i) adhesion could increase NF-kB activity by a mechanism different from the IkB degradation by the proteasome; (ii) LiCl did not modify NF-kB activity through a regulation of the proteasome activity.
Altogether, these results show that NF-kB activity plays major roles in drug resistance of leukemic cells. In these conditions, the regulation of NF-kB by GSK3b could involve an IkB-independent pathway.
Adhesion of U937 on osteoblasts supports drug resistance and triggers sFRP-1 secretion Osteoblasts play a key role in the maintenance of the hematopoietic niche and we asked for their potential role in drug resistance of AML. U937 cells were allowed , and are representative from two independent experiments. Right panel: U937 (n ¼ 3-8) and blasts from patients (n ¼ 8) were processed for CAM-DR assays. U937 cells or blasts from patients were preincubated or not with TDZD-8 (10 mM). As controls of GSK3b inhibition or of loading, b-catenin and actin levels were checked, respectively. SiRNA GSK3b was performed by electroporation of a 'smart pool' of siRNAs as indicated in Materials and methods section and cells were used 48 h after for CAM-DR assays. Survival was estimated by a MTT test. Data are expressed as percent of survival compared to the respective controls in Suspension or in Adhesion without DNR. **Po0.01 (comparison with control without GSK3b inhibition). (b) Phosphorylation state of GSK3b in U937 adherent (A) or in suspension (S) was evaluated with a specific antibody directed to the inactive form of GSK3b (GSK3 serine phosphorylated at position 9). Data are representative of two independent experiments.
Adhesion and Wnt pathways in chemoresistance of AML F De Toni et al to adhere onto human osteoblasts and apoptosis induced by DNR was measured by flow cytometry (Figure 6a ). In agreement with our previous results (Figure 1 ), 60% U937 in suspension died in response to DNR. Similarly to adhesion on fibronectin, adhesion of U937 onto osteoblasts decreased DNR-induced apoptosis (À11 and À26%, from two independent experiments, Figure 6a and not shown). LiCl pretreatment of U937 partially restored drug sensitivity, suggesting that GSK3b activity is required for drug resistance in both adhesion on fibronectin and on osteoblasts. When U937, in suspension, were preincubated with the culture medium conditioned by U937 adherent on osteoblasts, they became more resistant ( þ 23%) to DNR treatment (Figure 6b , bar No. 2, Po0.05). By contrast, the supernatant of osteoblasts alone (bar No. 1) did not modify chemosensitivity of leukemic cells. Significant amount of sFRP-1 (but not Dkk-1, not shown) was detected by Western blotting in the supernatant of osteoblasts with adherent U937 but not of osteoblasts alone (Figure 6b, right panel) . It should be noted that sFRP-1 was not detectable when U937 were incubated with osteoblasts in the absence of adhesive contacts (chamber with poreous membrane) or when U937 were allowed to adhere onto fibronectin (not shown). Importantly, immunodepletion of sFRP-1 from the supernatant restored basal sensitivity of U937 to DNR (Figure 6b , bar No. 3).
These results suggest that more relevant complex adhesion modes of leukemic cells could support drug resistance through the involvement of GSK3b regulation. Importantly, adhesion of leukemic cells on osteoblasts triggers secretion of Wnt antagonists able to modulate drug response of non-adherent leukemic cells.
Discussion
Microenvironmental factors are now considered to play a very important role in tumorigenesis and resistance to therapy (Hazlehurst et al., 2003; Kenny and Bissell, 2003; Prindull and Zipori, 2004) . In AML, cell proliferation and differentiation are controlled by the adhesion through engagement of integrin receptors (Bendall et al., 1998) , and morphogen pathways such as Wnt (Simon et al., 2005) . Therefore, we focused our interest on the role of both mechanisms in resistance to therapy. We confirm here that adhesion through integrin engagement triggers chemoresistance of AML blasts as previously shown by Matsunaga et al. (2003) . Moreover, we demonstrate that the blockade of the Wnt pathway by Wnt antagonists supports drug resistance of AML. These two mechanisms of resistance involve the activation of a cell survival pathway controlled by GSK3b/ NF-kB. As suggested by the fact that adhesion of leukemic cells on osteoblasts induces secretion of Wnt antagonists, a crosstalk between these two pathways of resistance could occur in vivo.
The interaction between a 4 b 1 (VLA-4) and stromal fibronectin was shown to support drug resistance of AML through PI 3-kinase activation, in vitro, and combination of a 4 b 1 -specific antibodies with chemotherapy strongly increased survival rate in vivo (Matsunaga et al., 2003) . Our data demonstrate that CAM-DR occurs for AML after adhesion onto fibronectin as well as onto osteoblasts. In our experimental conditions, both a 4 b 1 and a 5 b 1 -mediated adhesion induced resistance, and inhibition of PI 3-kinase did not abolish CAM-DR. a 5 b 1 has already been shown to mediate antiapoptotic and proliferative signals in AML (Bendall et al., 1998) . The discrepancy between our results and those of Matsunaga (Matsunaga et al., 2003) on the involvement of a 5 b 1 in CAM-DR of U937 leukemic cells could be explained by differences in experimental procedures, particularly the absence of serum in our CAM-DR assays, or by the origin of U937 cell line. It should be noted that, in Matsunaga's study, CAM-DR of AML blasts from patients was correlated with the expression of both a 4 b 1 and a 5 b 1 integrins. Depending on the context in vivo, either one integrin or the other, or both, could be involved in CAM-DR.
We found that different Wnt antagonists (sFRP-1, Dkk-1, Wnt5a) induced drug resistance at the same level as adhesion did. No sFRP-1 was detected in adherent U937 onto fibronectin, but adhesion of U937 on osteoblasts triggered sFRP-1 secretion. sFRP-1 has been shown to induce antiapoptotic effects in glioma (Roth et al., 2000) and leiomyoma (Fukuhara et al., 2002) . It protects fibroblasts from ceramide-induced apoptosis through the regulation of a p53/BCL-2 pathway (Han and Amar, 2004) . Because U937 are p53 negative and since we did not detect BCL-2 variations in our experiments (not shown), this mechanism is unlikely to be active in our system. Our data suggest that adhesion and Wnt antagonist treatment of leukemic blasts could modulate a common signaling pathway critical for cell survival in response to Effects of GSK3b inhibition on chemoresistance induced by Wnt antagonists. U937 cells in suspension were preincubated with the GSK3b inhibitor LiCl (10 mM) for 1 h before the addition of antagonists of the Wnt pathway (sFRP-1 10 mg/ml, Dkk-1 0.15 mg/ml, Wnt5a 10 ng/ml). Then survival to DNR treatment was measured by a MTT test. Data are expressed as percent of survival compared to the controls with DNR and are from three independent experiments. **Po0.01; ***Po0.001 (comparison with controls without Wnt antagonist or LiCl treatment).
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Proteolysis of b-catenin has been associated with proapoptotic effects in leukemic cells (Chung et al., 2002; Hwang et al., 2002) . However, in our experiments, b-catenin level was strongly decreased in resistant blasts treated with Wnt antagonists, and modulation of b-catenin level by siRNA did not significantly modify cell survival. Altogether, these results demonstrate that b-catenin is not responsible for drug resistance of leukemic blasts in adhesion or upon Wnt antagonist treatment. Upstream of b-catenin, GSK3b is a point of crosstalking between integrin-and Wnt-dependent signaling pathways. Our data demonstrate that GSK3b might be a critical therapeutic target in resistant blasts of AML. Indeed, pharmacological or genetic inhibition of GSK3b abolished drug resistance induced by adhesion or Wnt antagonist treatment. Moreover, we showed that GSK3b activity was triggered by adhesion onto fibronectin since dephosphorylation of the Ser(9) position required for GSK3b activation was detected in adherent blasts before DNR treatment. The involvement of active GSK3b in cell survival is poorly described. However, in some solid tumors, GSK3 inhibitors are thought to represent interesting future therapeutic tools since active GSK3b controls cell survival (Ghosh and Altieri, 2005; Ougolkov et al., 2005) or resistance to apoptosis induced by different stress (Liao et al., 2003) . GSK3b activation downstream of a 2 b 1 engagement has been described previously in a three-dimensional cell adhesion model (Ivaska et al., 2002) . Interestingly, in these experiments, dephosphorylation of the Ser(9) position of GSK3b is concomitant of Akt inhibition by the protein phosphatase PP2A. We currently check whether this pathway is relevant in our conditions.
We demonstrate that a GSK3b/NF-kB pathway plays key role in chemoresistance induced by adhesion onto fibronectin or Wnt antagonist treatment. The fact that an incomplete downregulation of GSK3b or NF-kB p65 subunit by siRNA is sufficient to restore chemosensitivity suggests that very active pools of GSK3b or p65 are involved in the adhesion/Wnt antagonists-dependent resistance. In agreement with the work of Landowski on Adhesion and Wnt pathways in chemoresistance of AML F De Toni et al CAM-DR of myeloma , we measured an activation of NF-kB in adherent U937 compared to cells in suspension. NF-kB is a major target in GSK3b-regulated cell survival (Hoeflich et al., 2000) and has been shown to be constitutively active in AML (Guzman et al., 2001 Deng et al., 2004; Takada et al., 2004) . Our data suggest that the regulation of NF-kB by GSK3b does not occur at the IkB level in our model. One major question raised by our results is the origin of sFRP-1 detected in the supernatant of osteoblasts and leukemic cells in co-culture, and the potential role of GSK3b in this secretion. Indeed both cell types have been described to secrete sFRP-1 and GSK3b might control cell survival through the regulation of sFRP-1 production. We have performed preliminary experiments 
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Relative cell number Relative cell number Figure 6 Adhesion on osteoblasts protects AML from genotoxic stress. (a) Serum-starved U937 treated or not with LiCl (10 mM) were allowed to adhere on osteoblasts and were then treated with DNR as described in Materials and methods section. After 24 h of incubation in serum supplemented medium, U937 were permeabilized and labeled with Apo2.7-PC5 to check apoptosis by flow cytometric analysis. Proportion of apoptotic cells in each condition is indicated in the histograms. Data are representative of two independent experiments. (b) Serum-starved U937 were preincubated with supernatants from flasks containing osteoblasts alone (bar No. 1) or osteoblasts plus adherent U937 (bars No. 2 and 3) before DNR treatment as indicated in Materials and methods section. After 24 h in serum containing medium, effects on survival were quantified by a MTT test. In some experiments, the osteoblast supernatant was immunodepleted of sFRP-1 (bar No. 3) before incubation with U937. Western blotting with anti-sFRP-1 antibody of unconcentrated supernatants (50 mg of total proteins) is shown. Recombinant sFRP-1 (Rec.sFRP-1) was used as control. Survival measurement is expressed as percent of control (DNR-treated U937) and was obtained from three independent experiments: *Po0.05.
Adhesion and Wnt pathways in chemoresistance of AML F De Toni et al by preincubation of osteoblasts or U937 with LiCl before starting co-culture. We have not measured significant variations of sFRP-1 amounts in supernatants obtained in control and LiCl assays (not shown). This result and the fact that adherent U937 on fibronectin did not secrete significant amount of sFRP-1 suggest that (i) osteoblasts could be the source of sFRP-1 (ii) the sFRP-1 secretion is not controlled by GSK3b.
In conclusion, our data demonstrate for the first time the involvement of GSK3b, under its active form, in chemoresistance induced by adhesion. Moreover, this pathway is also relevant to Wnt antagonist-induced survival, a new way of AML drug resistance that we have shown. Importantly, our results suggest also that the adhesion-dependent secretion of Wnt antagonists by osteoblasts could strongly reinforce resistance to chemotherapy in the hematopoietic stem cell niche by inducing a double resistance mechanism (i.e. adhesion and antiWnt production). Thus, novel antileukemic approaches should include targeting of the GSK3b/NF-kB pathway beside conventional chemotherapeutic agents or specific antioncogenic drugs. It could allow to target specifically resistant adherent leukemic cells but also their neighbors conditioned by Wnt antagonists.
Materials and methods
Antibodies, Wnt products and GSK3b inhibitors
Monoclonal antibodies against b-catenin, GSK3a/b or integrin subunits (a 5 , P1D6; a 4 , P4G9) were from Cell Signaling Technology (Beverly, MA, USA), Biosource International (Camarillo, CA, USA) and Dako (Carpinteria, CA, USA), respectively. Mouse IgG3 isotype control was from BD Biosciences, Pharmingen. Monoclonal anti-PARP (poly(ADPribose) polymerase) and antiactin were purchased from BD Transduction Laboratories and Sigma, respectively. Polyclonal antibodies directed to NF-kB (p65), IkB, lamin B, FRP-1 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal antibody against caspase 3 came from Cell Signaling Technology. Horseradish-peroxydase-conjugated secondary antibodies against mouse, rabbit or goat immunoglobulins were from Cell Signalling Technology and Santa Cruz Biotechnology, respectively. sFRP-1 was a generous gift from Dr JS Rubin (Laboratory of Cellular and Molecular Biology, NIH, Bethesda, MD, USA) and Wnt3a, Wnt5a and Dkk-1 were purchased from RD Systems (Lille, France). GSK3b inhibitors: LiCl and SB-216763 were from Sigma, and 3-(3-Carboxy-4-chloroanilino)-4-(3-nitrophenyl)maleimide and TDZD-8 were obtained from Calbiochem (Darmstadt, Germany).
Cells
Fresh AML cells were obtained from bone marrow of 35 patients upon informed consent, using Ficoll-Hypaque density-gradient centrifugation. Blasts were immediately cryopreserved in Iscove's modified Dulbecco's medium with dimethyl sulfoxide and fetal calf serum (FCS). All patients were diagnosed according to WHO classification at the Hematology Department of Toulouse University Hospital (France). Leukemias were characterized in terms of morphology (French American British classification), karyotype, immunophenotyping, and FLT3 gene mutation (internal tandem duplication; FLT3/ITD) mutation. Bone marrow samples contained more than 80% leukemic blasts after processing. For in vitro experiments, blasts were immediately resuspended in RPMI-1640 with 10% FCS after thawing. Cells were then washed twice in RPMI containing HEPES (10 mM) and 0.2% BSA. Only samples with more than 80% of cell survival estimated by Trypan blue were processed. The human leukemic cell line U937 was purchased from American Type Culture Collection (ATCC; Rockville, MD, USA).
Fresh human osteoblasts were prepared by the explant technique (Siggelkow et al., 1999) from normal vertebral fragments obtained at the Pediatric Surgery Department of Toulouse University Hospital (France).
Cell culture U937 cells and human osteoblasts were grown at 371C in 5% CO 2 in RPMI-1640 or DMEM medium, respectively, containing 10% FCS, 50 mg/ml penicillin, and 50 mg/ml streptomycin. Osteoblasts were used at passages 1-5 and characterized by N-cadherin and phosphatase alkaline expression.
Western blotting
For Western blot, 0.5-3 Â 10 6 cells resuspended in cell culture medium without serum were reduced in Laemmli sample buffer. After boiling for 10 min, proteins were resolved on polyacrylamide SDS gel (SDS-PAGE) and then transferred to nitrocellulose (membrane Hybond-C super, Amersham Pharmacia Biotech) using a liquid transfer apparatus (Amersham Pharmacia Biotech). The membrane was blocked 1 h at room temperature in Tris-buffered saline (TBS) containing 1% fatfree milk and 1% bovine serum albumin (BSA). The proteins were detected by blotting overnight at 41C with the appropriate monoclonal or polyclonal antibodies in TBS, 0.1% Tween, 1% fat-free milk and 1% BSA, followed by incubation with either anti-mouse or anti-rabbit IgG antibody coupled to horseradish peroxidase. Detection was achieved using a chemoluminescent probe (ECL, Amersham Pharmacia Biotech).
Transfection of siRNA U937 cells were transfected using the Amaxa nucleofection technologyt (Amaxa, Koeln, Germany). Briefly, cells were resuspended in Amaxa solution kit Vt, following the Amaxa guidelines for cell line transfection that we have optimized for U937 cells. 6 Â 10 6 U937 cells in 100 ml solution kit V were mixed or not with 200 nM siRNA GSK3b, 200 nM siRNA p65 or with 200 nM siRNA scramble (Dharmacon Inc., Lafayette, CO, USA), and immediately nucleofected with an Amaxa Nucleofector apparatus (Amaxa, program V01). Cells were then immediately transferred into wells containing 371C prewarmed culture medium in six-well plates. After transfection, cells were cultured from 24 to 48 h before analysing by Western blotting. Decrease of GSK3b and p65 was observed at 24 h but was maximal at 48 h. Therefore, tests of drug sensitivity were performed at 48 h postnucleofection.
Drug cytotoxicity studies and induction of CAM-DR In all, 96 wells microtiter plates (MaxiSorp Immuno Plate, Nunc, Denmark) were coated overnight at 41C with 40 mg/ml of human fibronectin (Roche Molecular Biochemicals, Mannheim, Germany) in a final volume of 50 ml in PBS and subsequently blocked with 1% fatty acid-free BSA in PBS, 1 h at room temperature. AML cells were diluted at 300 000/ml overnight and then were serum starved for 1 h, incubated or not with Wnt modulators (sFRP-1, 10 mg/ml; Wnt3a, 20 ng/ml; Dkk-1, 0.15 mg/ml; Wnt5a, 10 ng/ml) or GSK3b inhibitors.
Then, cells were allowed to adhere on fibronectin-coated microtiter plate 96 wells (10 5 cells/well) for 1 h at 371C or maintained in suspension. In some experiments, adhesion assays were performed on wells coated with a 4 b 1 (1 mg/ml) or a 5 b 1 (0.1 mg/ml) antibodies. Cells in suspension or adherent were treated with 0.5 mM DNR (Laboratoire Roger Bellon, Neuilly-sur-Seine, France) for 1 h at 371C. At the end of the incubation period, cells were washed and incubated in serumcontaining medium for 24 h at 371C. Cell viability was then quantified by methyl thiazolyl tetrazolium (MTT) assay (Sigma). Experiments were performed in triplicate.
Preparation of cell extracts U937 cells (5 Â 10 6 ) were serum starved and untreated or treated with LiCl (10 mM) for 1 h and subsequently plated on fibronectin (1 h) or maintained in suspension. In some experiments, DNR treatment was then performed (1 h). Then cells were washed with ice-cold phosphate-buffered saline, harvested, and resuspended in 0.4 ml of buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride). At 10 min after, 23 ml of 10% Nonidet P-40 was added and mixed for 2 s. Nuclei were separated from cytosol by centrifugation at 13 000 g for 10 s and were resuspended in 50 ml of buffer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.1 mM phenylmethylsulfonylfluoride). After 30 min at 41C, lysates were separated by centrifugation (13 000 g, 30 s). Supernatant containing nuclear proteins and cytosol extracts were processed for measurement of protein concentration. Samples were stored at À201C.
Gel EMSA
The gel mobility shift assays were performed with a synthetic double-stranded 31-mer oligonucleotide (5 0 -ACAAGGGAC TTTCCGCTGGGGACTTTCCAGG-3 0 ) containing the NFkB-binding site from sequences of the human immunodeficiency virus long terminal repeat, 5-end-labeled with [g 32 P]ATP using the T4 polynucleotide kinase. Of the nuclear extract, 5 mg was incubated in 20 ml of binding buffer (20 mM HEPES, pH 7.9, 100 mM KCl, 20% glycerol, 0.3 mg/ml sonicated doublestranded salmon sperm DNA, protease inhibitor mixture (Sigma)) for 20 min in ice. Then 32 P-labeled oligonucleotide probe (approximately 30 000-50 000 cpm) was added, and the reaction mixture was incubated for 20 min at room temperature. For reactions involving competitor oligonucleotides, the unlabeled competitor and the labeled probes were premixed before addition to the reaction mixture. To prove the involvement of the NF-kB p65 subunit in DNA binding, p65 Ab was added in some assays inducing a shift of the DNA-NF-kB complex. The samples were analysed on 6% acrylamide gels, which were made in 50 mM Tris borate EDTA buffer and electrophoresis was carried out at 100 V/ cm for 1.30 h. Gel contents were transferred to Whatman DE-81 paper, dried, and exposed overnight at À801C with an intensifying screen.
Competitive cell adhesion assay Adhesion assays were performed in 96-well plates coated with fibronectin as described in the experimental section of drugcytotoxicity studies. During serum starvation (1 h), U937 in suspension were incubated with blocking integrin antibodies (anti-a 4 , P4G9 or anti-a 5 , P1D6) at concentrations indicated, and cells (0.1 Â 10 6 ) were then allowed to adhere on fibronectin for 1 h. After two gentle washes with PBS, cells were fixed for 30 min with a Karnovsky solution (2% paraformaldehyde-0.1% glutaraldehyde in PBS, pH 7.4) and then stained for 5 min with a 0.1% crystal violet solution. Cells were rinsed four times under running water, and the stain retained by cells was solubilized in 0.1 ml of 2% sodium deoxycholate, and A 595 was measured to determine cell adhesion.
Adhesion of AML cells on osteoblasts
Serum-starved U937 (1 h; 1 Â 10 6 ) were plated on osteoblasts at nearly confluence (0.4 Â 10 6 ) for 1 h in RPMI. In all, 50À60% adhesion was quantified in these conditions. Remaining suspended U937 were discarded and DNR (0.5 mM) was applied for 1 h. At the end of incubation, cells were cultured in RPMI 10% SVF for 24 h and then analysed for apoptosis by flow cytometric analysis using APO2.7-PC5 labeling (Immunotech, Marseille, France). In some experiments, osteoblasts were cultured at confluence for 48 h in DMEM with 1% SVF. Then serum-starved U937 were allowed to adhere on osteoblasts for 1 h and incubation of remaining adherent U937 was further continued in DMEM 1% SVF for 24 h. At the end of the incubation, supernatants of flasks with osteoblasts alone or osteoblasts plus U937 were centrifuged and incubated with serum-starved U937 for 1 h before DNR treatment as described in drug cytotoxicity studies section above. U937 survival was estimated at 24 h by a MTT test. When indicated supernatants were processed for immunodetection of sFRP-1 or Dkk-1 by Western blotting or for immunoprecipitation of sFRP-1 (5 mg antibody/720 mg total protein) and further drug cytotoxicity assays.
Statistical analysis
Student's t test was used for in vitro experiments analysis.
